U
AMPH icon

UBS’s Amphastar Pharmaceuticals AMPH Stock Holding History

UBS’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$10K Buy
+871
New +$9.07K ﹤0.01% 8810

Other funds holding AMPH

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS's AMPH Position: Q3 2014 in Review

UBS opened a new position in Amphastar Pharmaceuticals (AMPH) in Q3 2014: 871 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #8810 among its holdings.

45 funds tracked by Wall St. Rank hold AMPH as of Q3 2014.

  • UBS held 871 shares of Amphastar Pharmaceuticals worth $10K as of Q3 2014.
  • Amphastar Pharmaceuticals was a new UBS position in Q3 2014.
  • Amphastar Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #8810 holding.
  • 45 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.